簡(jiǎn)要描述:
YY0178RAnti-OCT2 (organic cat-ion transporter2)B細(xì)胞特異性轉(zhuǎn)錄因子抗體50ug/100ug
更新時(shí)間:2024-08-18;廠商性質(zhì):經(jīng)銷商;覽量:600
YY0178R Anti-OCT2 (organic cat-ion transporter2)B細(xì)胞特異性轉(zhuǎn)錄因子抗體 50ug/100ug
YY0782R Anti-IL-6 (Interleukin-6) mouse、rat 白介素6抗體 50ug/100ug
YY0379R Anti-IL-6(Interleukin-6/interferon, beta 2)mouse rat 白介素6抗體 50ug/100ug
YY0780R Anti-IL-8(Interleukin-8)rat mouse 白介素8抗體 50ug/100ug
YY0317R Anti-ILK-1 (Integrin-linked protein kinase 1) 整合素連接激酶-1抗體 50ug/100ug
YY1291R anti-ING1/p33(inhibitor of growth gene 1) 生長(zhǎng)抑制因子基因1抗體 50ug/100ug
YY1032R Anti-Inhibin α 抑制素α抗體 50ug/100ug
YY0056R Anti-Insulin 胰島素抗體 50ug/100ug
YY0047R Anti-Insulin Receptor-α(ISR-α) 胰島素受體-α抗體 50ug/100ug
YY0789R Anti-Insulin(1-51 protein) 胰島素1-51蛋白抗體 50ug/100ug
YY1057R Anti-Integrin α3β1 整合素α3β1抗體 50ug/100ug
YY0178R Anti-OCT2 (organic cat-ion transporter2)B細(xì)胞特異性轉(zhuǎn)錄因子抗體 50ug/100ug
YY1051R Anti-Integrin α4β7/LPAM-1 (Lymphocyte Peyer’s patch Adhesion Molecule 1/Integrin alpha4,beta7) 整合素α4β7抗體 50ug/100ug
YY1310R anti-Integrin avb3 整合素avb3抗體 50ug/100ug
YY1274R Anti-Integrin αE2/CD103 整合素αE2抗體 50ug/100ug
YY1109R Anti-IQGAP1 支架蛋白抗體 50ug/100ug
YY0242R Anti-IRS P53 (Insulin receptor suRCtrate P53) 胰島素受體底物p53蛋白抗體 50ug/100ug
YY0172R Anti-IRS-1 胰島素受體底物-1抗體 50ug/100ug
YY0173R Anti-IRS-2 胰島素受體底物-2抗體 50ug/100ug
YY0186R Anti-IRS-3 胰島素受體底物-3抗體 50ug/100ug
YY0187R Anti-IRS-4 胰島素受體底物-4抗體 50ug/100ug
YY0681R Anti-ISR(Insulin Receptor) 胰島素受體抗體 50ug/100ug
YY0178R Anti-OCT2 (organic cat-ion transporter2)B細(xì)胞特異性轉(zhuǎn)錄因子抗體 50ug/100ug
間接染色法如果檢查未知抗原,先用已知未標(biāo)記的特異抗體(*抗體)與抗原標(biāo)本進(jìn)行反應(yīng),作用一定時(shí)間后,洗去未反應(yīng)的抗體,再用標(biāo)記的抗抗體即抗球蛋白抗體(第二抗體)與抗原標(biāo)本反應(yīng),如果*步中的抗原抗體互相發(fā)生了反應(yīng),則抗體被固定或與熒光素標(biāo)記的抗抗體結(jié)合,形成抗原-抗體-抗抗體復(fù)合物,再洗去未反應(yīng)的標(biāo)記抗抗體,在熒光顯微鏡下可見(jiàn)熒光。在間接染色法中,*步使用的未用熒光素標(biāo)記的抗體起著雙重作用,對(duì)抗原來(lái)說(shuō)起抗體的作用,對(duì)第二步的抗抗體又起抗原作用。如果檢查未知抗體則抗原標(biāo)本為已知的待檢血清為*抗體,基他步驟和檢查抗原相同。
YY0178R Anti-OCT2 (organic cat-ion transporter2)B細(xì)胞特異性轉(zhuǎn)錄因子抗體 50ug/100ug